The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

@article{Rodby2000TheIT,
  title={The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.},
  author={Roger A. Rodby and Richard D Rohde and William Clarke and Lawrence G. Hunsicker and Debra A Anzalone and Robert C. Atkins and Eberhard Ritz and E Jonathan Lewis},
  journal={Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association},
  year={2000},
  volume={15 4},
  pages={487-97}
}
BACKGROUND Diabetic nephropathy is the most common cause of end-stage renal disease in the developed world. Angiotensin-converting enzyme inhibitors have been demonstrated to be renoprotective in type I diabetes and are now the standard of care for both hypertensive and non-hypertensive type I diabetic patients with any level of proteinuria. The role of blockade of the renin-angiotensin system in type II diabetic patients is not defined. The Collaborative Study Group has initiated the… CONTINUE READING
28 Extracted Citations
0 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…